Hydro completed the acquisition of Vale's remaining shareholding in Mineração Paragominas S.A. (MPSA) on 15 December 2016. The transaction is the second and final step of the MPSA put/call arrangements agreed in 2011 in connection with Hydro's acquisition of the majority of Vale's aluminium assets in Brazil. Hydro now owns 100% of MPSA's shares.
Hydro's net payment, after adjustments resulting from the completion of outstanding contractual arrangements with Vale, was USD 113 million. Hydro expects the transaction to have a positive impact for Bauxite & Alumina of approximately USD 45 million on its result in the fourth quarter of 2016, of which USD 30 million will be excluded from underlying earnings.
Investor contact
Contact Olena Lepikhina
Cellular +47 96853035
E-mail [email protected]
Press contact
Contact Halvor Molland
Cellular +47 92979797
E-mail [email protected]


SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Apple Turns 50: From Garage Startup to AI Crossroads
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



